New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.42 1.08 +1.85%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Bristol Myers Squibb Company 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 11:10 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 11 added · 9 removed · 42 modified; 9 with only figures updated

  1. Modified · EXECUTIVE SUMMARY

    During the first quarter of In 2026, we made meaningful progress advancing our pipeline, highlighted by: (i) positive interim Phase III results from the SUCCESSOR‐2 study of oral mezigdomide in RRMMFDA acceptance of our NDA for iberdomide in RRMM with a PDUFA date of August 17, 2026; (ii) positive Phase III results from the SCOUT-HCM trial of Camzyos in adolescents with symptomatic oHCMFDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027; (iii) positive top‐line interim Phase II results from a Phase II trial for Reblozylthe ROSETTA Lung-02 study of pumitamig in adultspatients with Alpha (α)-Thalassemia, previously untreated advanced NSCLC; (iv) positive interim top‐line results from atwo Phase III trialstudies conducted in China for iza-bren in previously treatedheavily pretreated, unresectable locally advanced or metastatic TNBC, and recurrent or metastatic ESCC; and (v) FDA acceptance of our NDAsNDA for iberdomideCamzyos in combinationadolescents with standard therapy for patients with RRMMsymptomatic oHCM with a PDUFA date of September 30, 2026. Additionally, Sotyktu was approved in the U.S. and EU for the treatment of adults with active PsA and Opdivo was approved in the U.S. and EU for cHL.